Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intercept Pharmaceuticals
Biotech
Lilly inks $50M deal for biotech's FXR program
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat IBD, sending the biotech's stock up 244%.
Gabrielle Masson
Feb 26, 2025 5:35am
Ipsen, Genfit report phase 3 rare liver disease success
Jun 30, 2023 6:15am
Enanta pulls plug on NASH, seeks to offload assets for combos
Oct 4, 2021 8:40am
Ex-Intercept CMO Campagna lands at Q32
Mar 9, 2021 8:45am
Intercept loses chief medical officer months after CEO's exit
Feb 23, 2021 7:20am
CymaBay tees up new phase 3 study for resurrected liver drug
Nov 16, 2020 8:04pm
